Emerging data suggest this peptide, a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may represent a promising advancement for obesity treatment. Initial https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide